MedTrace Logo

Efficacy of Bioactive Collagen Peptide Compared to Glucosamine and Chondroitin Sulphate in Grade I-III Knee Osteoarthritis

NCT07746466 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2026-08-10

No results posted yet for this study

Summary

Brief Summary

The goal of this clinical trial is to learn whether bioactive collagen peptide works as well as glucosamine and chondroitin sulphate for improving pain, stiffness, physical function, and quality of life in adults with mild to moderate knee osteoarthritis (Kellgren-Lawrence grades I to III).

The main questions it aims to answer are:

Does bioactive collagen peptide improve knee pain, stiffness, and physical function over 12 weeks? Does bioactive collagen peptide improve health-related quality of life? Is bioactive collagen peptide as safe and effective as glucosamine and chondroitin sulphate for treating knee osteoarthritis?

Researchers will compare bioactive collagen peptide with glucosamine and chondroitin sulphate to determine whether one treatment provides greater improvement in symptoms and quality of life.

Participants will:

Be randomly assigned to receive either bioactive collagen peptide once daily or glucosamine and chondroitin sulphate twice daily for 12 weeks.

Attend study visits at the start of the study and again at 6 and 12 weeks. Complete questionnaires about their knee pain, stiffness, physical function, and overall health-related quality of life at each visit.

Be monitored for treatment adherence, use of rescue pain medication, and any side effects throughout the study.

The information from this study may help healthcare providers better understand whether bioactive collagen peptide is an effective and safe non-surgical treatment option for people with symptomatic knee osteoarthritis.

Conditions

  • Knee Osteoarthritis (Kellgren-Lawrence Grade 1-3)

Interventions

DIETARY_SUPPLEMENT

Bioactive Collagen Peptide

Participants assigned to this intervention receive oral bioactive collagen peptide (Movgen®), containing fish collagen 4,000 mg and Curcuma longa extract 250 mg. The supplement is administered orally at a dose of 8 g once daily for 12 weeks as conservative treatment for symptomatic Kellgren-Lawrence grade I-III knee osteoarthritis.

DIETARY_SUPPLEMENT

Glucosamine and Chondroitin Sulphate

Participants assigned to this intervention receive an oral combination of glucosamine sulphate and chondroitin sulphate (Gebon Plus®), containing glucosamine sulphate 400 mg, chondroitin sulphate 300 mg, methylsulfonylmethane 200 mg, hyaluronic acid 100 mg, Boswellia serrata extract 40 mg, Smilax chinensis extract 30 mg, and Curcuma longa extract 30 mg. The supplement is administered orally twice daily for 12 weeks as conservative treatment for symptomatic Kellgren-Lawrence grade I-III knee osteoarthritis.

Sponsors & Collaborators

  • Liaquat National Hospital & Medical College

    lead OTHER

Principal Investigators

  • Sumaiya Khan, MBBS, MRCS(Ire), FCPS · Liaquat National Hospital and Medical College

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-01
Primary Completion
2025-08-15
Completion
2025-08-17

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07746466 on ClinicalTrials.gov